Gain detailed insights into the trading activity of Congress members for DexCom on our government trades page. Stay updated on how elected officials are investing in DXCM.

DexCom - Government Trades

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Couple Charged In $1 Million Lululemon Shoplifting Ring

News

Price Target

Markets

Analyst Ratings

Trading Ideas

CBRL

CNXC

DXCM

LULU

STNE

Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday

Netflix-Inc- copy

Upgrades

Pre-Market Outlook

MNDY

NFLX

This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Screenshot 2024-12-03 at 7.43.04 PM

Biotech

General

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Modern,Hospital,And,Communication,Network,Concept.,Medical,Technology.,Medtech.

Analyst Color

Downgrades

Health Care

Movers

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

STAA

TMDX

TNDM

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

hedge fund ai

Hedge Funds

ALAB

CPNG

FLUT

GOOGL

MSFT

TTWO

Billionaire investor Chase Coleman&#39;s hedge fund, Tiger Global Management, filed its latest Form 13F on Thursday and disclosed its trading activity from the prior quarter.

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

defence analysts

Earnings

These Analysts Revise Their Forecasts On DexCom Following Q3 Results

Stock Market Data - chart illustration

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

GOOG

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks.

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What&#39;s Driving Markets Friday?

movers image

COUR

CPRI

JOBY

MASI

SBSW

TBBK

TVGN

Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

dexcom

Management

After-Hours Center

DexCom reported its third-quarter results after Thursday&#39;s closing bell. Here&#39;s a look at the details from the report.

DexCom Stock Drops After Q3 Results, Announces C-Suite Transition

tesla-bull-ai

Large Cap

Mid Cap

Small Cap

CARR

CBRE

LRCX

NDAQ

SPGI

TMUS

XLRE

Tech stocks outperformed on Thursday, driven by Tesla Inc. (NASDAQ:TSLA), which skyrocketed 18% in midday trading following stronger-than-expected quarterly financial results.

Tech Stocks Rebound, Tesla Marks Best 1-Day Gain Since March 2021, Gold Rises As Treasury Yields Ease: What&#39;s Driving Markets Thursday?

DexCom Inc

<p>Throughout the last three months, 11 analysts have evaluated DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, a high estimate of $115.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $93.36.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737054064_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DexCom analyst ratings.</strong></a></p>
<h2>All You Need to Know About DexCom</h2>
<p>Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.</p>
<h3>Financial Insights: DexCom</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of <strong>1.97%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>13.54%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DexCom's ROE excels beyond industry benchmarks, reaching <strong>6.1%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>2.05%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.31</strong>, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: DexCom Through The Eyes Of 11 Analysts

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>JP Morgan cut the price target for <strong>The Procter &amp; Gamble Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from $186 to $181. JP Morgan analyst Andrea Teixeira maintained an Overweight rating. Procter &amp; Gamble shares closed at $159.65 on Wednesday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<ul>
<li>Canaccord Genuity slashed <strong>Concentrix Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NYSE">CNXC</a>) price target from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Concentrix shares closed at $47.47 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for <strong>The Hershey Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from $171 to $151. JP Morgan analyst Ken Goldman maintained a Neutral rating. Hershey shares closed at $155.31 on Wednesday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities increased the price target for <strong>Cracker Barrel Old Country Store, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) from $48 to $51. Truist Securities analyst Jake Bartlett maintained a Hold rating. Cracker Barrel shares closed at $57.57 on Wednesday. <a href="https://www.benzinga.com/quote/CBRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised <strong>DexCom, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) price target from $86 to $104. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. DexCom shares settled at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised <strong>The Bank of New York Mellon Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $94 to $98. Deutsche Bank analyst Brian Bedell maintained a Buy rating. Bank of New York Mellon shares closed at $82.04 on Wednesday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed <strong>StoneCo Ltd</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $19 to $9. Citigroup analyst Gustavo Schroden downgraded the stock from Buy to Neutral. StoneCo shares closed at $8.74 on Wednesday.  <a href="https://www.benzinga.com/quote/STNE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for <strong>Lululemon Athletica Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from $428 to $437. JP Morgan analyst Matthew Boss maintained an Overweight rating. Lululemon shares settled at $376.66 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised <strong>Vitesse Energy, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) price target from $28 to $31. Northland Capital Markets analyst Bobby Brooks maintained an Outperform rating. Vitesse Energy shares closed at $27.12 on Wednesday. <a href="https://www.benzinga.com/quote/VTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised <strong>The Goldman Sachs Group, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) price target from $550 to $605. JP Morgan analyst Kian Abouhossein maintained an Overweight rating. Goldman Sachs shares closed at $605.92 on Wednesday. <a href="https://www.benzinga.com/quote/GS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></strong></li>
</ul>


<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Baird analyst Jeff Johnson upgraded the rating for <strong>DexCom, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raised the price target from $86 to $104. DexCom shares closed at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Enders upgraded <strong>monday.com Ltd</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from Neutral to Buy but lowered the price target from $302 to $298. Monday.Com shares closed at $234.15 on Wednesday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst David Joyce upgraded the rating for <strong>Netflix, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Neutral to Buy and announced a $955 price target. Netflix shares closed at $848.26 on Wednesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joseph Spak upgraded <strong>Dana Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) from Neutral to Buy and raised the price target from $11 to $18. Dana shares closed at $12.07 on Wednesday. <a href="https://www.benzinga.com/quote/DAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Benjamin Nolan upgraded the rating for <strong>Canadian National Railway Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) from Hold to Buy but lowered the price target from $132 to $120. Canadian National Railway shares closed at $100.69 on Wednesday. <a href="https://www.benzinga.com/quote/CNI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying NFLX stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png" alt="" class="wp-image-736905" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></strong></li>
</ul>


WIIM

DexCom shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $86 to $104.

<p>Baird  analyst Jeff Johnson   upgrades DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raises the price target from $86 to $104.</p>


Baird Upgrades DexCom to Outperform, Raises Price Target to $104

DexCom shares are trading higher after the company issued Q4 revenue expectations above estimates.

Guidance

DexCom Currently Anticipates FY25 Total Revenue Of $4.60B, Representing Expected Growth Of 14% Over 2024; Est $4.608B

<p>For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2023. In conjunction with the preliminary fourth quarter results, the company is also updating 2024 non-GAAP gross profit margin and non-GAAP operating margin guidance to 62% and 19% respectively.&nbsp;</p>
<p>Fourth quarter gross margin is expected to be adversely impacted by a non-cash charge primarily related to inventory damaged in transit and certain build configurations that lowered production yield for the quarter.</p>


DexCom Expects Q4 Total Revenue Of At Least $1.113B, Up 8% YoY (Est $1.097B); Expects Gross Margin To Be Adversely Impacted By Non-cash Charge

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>DexCom</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for DexCom.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $139,269, and 8 are calls, for a total amount of $460,585.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $95.0 for DexCom over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of DexCom stands at 2165.5, with a total volume reaching 2,631.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $95.0, throughout the last 30 days.</p>
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736186430_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.7</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$75.00</td>
<td>$109.4K</td>
<td>159</td>
<td align="right">76</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.6</td>
<td>$80.00</td>
<td>$82.1K</td>
<td>10.4K</td>
<td align="right">281</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.9</td>
<td>$2.75</td>
<td>$2.8</td>
<td>$82.00</td>
<td>$77.2K</td>
<td>99</td>
<td align="right">576</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.3</td>
<td>$82.00</td>
<td>$60.0K</td>
<td>99</td>
<td align="right">826</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$1.95</td>
<td>$77.00</td>
<td>$51.8K</td>
<td>19</td>
<td align="right">513</td>
</tr>
</tbody>
</table>
</p>
<h3>About DexCom</h3>
<p>Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.</p>
<p>In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>DexCom's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,506,236, with DXCM's price down by -0.53%, positioned at $80.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $94.66666666666667.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for DexCom, targeting a price of $99.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $91.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for DexCom, targeting a price of $94. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Decoding DexCom's Options Activity: What's the Big Picture?

<p>Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $120,660, and 5 were calls, valued at $426,440.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $100.0 for DexCom, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of DexCom stands at 701.83, with a total volume reaching 1,211.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $75.0 to $100.0, throughout the last 30 days.</p>
<h3>DexCom Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735576230_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$135.2K</td>
<td>2.5K</td>
<td align="right">234</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$80.00</td>
<td>$130.0K</td>
<td>2.5K</td>
<td align="right">316</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.95</td>
<td>$2.75</td>
<td>$2.95</td>
<td>$76.00</td>
<td>$59.0K</td>
<td>98</td>
<td align="right">202</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$80.00</td>
<td>$56.2K</td>
<td>790</td>
<td align="right">40</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$75.00</td>
<td>$54.2K</td>
<td>38</td>
<td align="right">67</td>
</tr>
</tbody>
</table>
</p>
<h3>About DexCom</h3>
<p>Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.</p>
<p>In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 518,458, the DXCM's price is down by -3.01%, now at $77.82. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 38 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $94.66666666666667.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on DexCom, which currently sits at a price target of $91.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on DexCom with a target price of $94.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on DexCom with a target price of $99. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Smart Money Is Betting Big In DXCM Options

<p><a href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" title="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom">https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom</a></p>


Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments

Macro Notification

Market Summary

Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

<ul>
<li><i>Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform</i></li>
<li><i>Dexcom GenAI-enabled technology will leverage Google Cloud's Vertex AI platform and Gemini models and will initially enhance Stelo's Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep</i></li>
<li><i>Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health</i></li>
<li><i>Dexcom to speak on the future of health AI at CES 2025</i></li>
</ul>


Dexcom Launched Proprietary Generative AI Platform To Integrate GenAI Into Glucose Biosensing

<p><strong>DexCom's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 7.58% since its last report. The company recently reported that it has <strong>8.42 million shares sold short</strong>, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.38 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734367523_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 3.83%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into DexCom's Recent Short Interest

<p>Citigroup  analyst Joanne Wuensch   maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $85 to $91.</p>


Citigroup Maintains Buy on DexCom, Raises Price Target to $91

<p>Wells Fargo  analyst Larry Biegelsen   maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and raises the price target from $90 to $94.</p>


Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $94

Watching Shares Of DexCom; Traders Circulating Note American Diabetes Association Updates Standards To Recommend Continuous Glucose Monitoring For Non-Insulin Type 2 Diabetes Patients, Paving Way For Broader Coverage And Market Growth; Bank Of America Reiterates Buy Rating On Dexcom Highlighting Long-Term Earnings Potential

<p>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a high estimate of $120.00, and a low estimate of $85.00. Highlighting a 1.12% decrease, the current average has fallen from the previous average price target of $99.56. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733770860_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DexCom analyst ratings.</strong></a></p>
<h2>All You Need to Know About DexCom</h2>
<p>Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.</p>
<h3>A Deep Dive into DexCom's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> DexCom's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>1.97%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> DexCom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>13.54%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DexCom's ROE excels beyond industry benchmarks, reaching <strong>6.1%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> DexCom's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.05%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> DexCom's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.31</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From DexCom Analyst Ratings

<p>Canaccord Genuity  analyst William Plovanic   maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $89 to $99.</p>


Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $99

Legal

Press Releases

DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dexcom Reports Third Quarter 2024 Financial Results

Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day

Dexcom and ŌURA Announce Strategic Partnership

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.

Baird

Citigroup

Wells Fargo

Canaccord Genuity

Bernstein

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier


Kevin HernHouse (R-OK)	$50K - $100K	stock	Sale	Jan 15, 2025	Dec 31, 2024	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Oct 15, 2023	Sep 12, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale (Partial)	Sep 16, 2023	Aug 21, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale (Partial)	Oct 16, 2022	Sep 28, 2022	House

Government Trades

DexCom Inc

top performing DXCM trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga